Navigation Links
Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
Date:9/4/2008

Interleukin Genetics Plans to Continue Efforts to Out-License Intellectual

Property

WALTHAM, Mass., Sept. 4 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), and Access Business Group International LLC, a division of Alticor Inc., have reached an agreement that will increase access to all intellectual property related to genetic tests jointly developed by Interleukin Genetics and Access Business Group under their research agreements. In turn, this will permit the expansion of Interleukin Genetics' distribution network for such genetic tests. Under the agreement, Access Business Group's existing license to the Interleukin Genetics' intellectual property will become non-exclusive.

Interleukin Genetics will have the right to brand, market, sell and distribute all genetic tests developed using its existing and future intellectual property, either itself or through additional third party licensees. Access Business Group will continue to distribute the Heart Health and General Nutrition genetic tests under the Gensona(R) brand name. The agreement will continue to allow Interleukin Genetics to have exclusive ownership of all inventions relating to genetic tests arising from research programs between the companies.

Lewis H. Bender, Chief Executive Officer at Interleukin Genetics, commented, "This is an excellent agreement for Interleukin Genetics as we now have the opportunity to aggressively pursue new partnerships for distribution of the genetic tests and intellectual property created over the years with our partner, Access Business Group. We are excited to continue our current efforts to out-license our intellectual property to companies in the biotechnology, molecular diagnostic, pharmaceutical, direct sales and consumer products areas."

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics, its products and ongoing programs, please visit http://www.ilgenetics.com.

About Alticor and Access Business Group

Alticor (http://www.alticor.com) is the parent company of Amway Corp., Quixtar Inc., Access Business Group LLC and Alticor Corporate Enterprises. Headquartered in Ada, Michigan, USA, Alticor and its affiliates offer products, business opportunities, and product development, manufacturing and logistic services in more than 80 countries and territories worldwide. In its most recent financial year, the company reported worldwide sales of more than $7.1 billion. For further information, please contact Alticor's media information line at 616-787-7565 or e-mail Alticor's media relations staff at mediainfo@alticor.com. Part of the Alticor family of companies, Access Business Group is a team of vertically integrated business-to-business experts. Access Business Group provides product development, sourcing, manufacturing, printing, packaging and distribution. Access Business Group offers expertise in nutrition, personal care, home care and beauty.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Announces Management and Board Appointments
2. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
3. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
4. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
5. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
6. Interleukin Genetics Retains Top Life Science Communications Firms
7. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
8. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
9. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
10. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Alex,s Lemonade ... announced that that it will open a state-of-the-art bioinformatics ... childhood cancer research. This announcement comes as Liz ... attends the National Cancer Moonshot Summit in ... Dr. Biden as a participant and advocate of pediatric ...
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... DIEGO , June 27, 2016  Sequenom, Inc. ... committed to enabling healthier lives through the development of ... Court of the United States ... courts that the claims of Sequenom,s U.S. Patent No. ... patent eligibility criteria established by the Supreme Court,s Mayo ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition of the ... offering. The report forecasts the ... at a CAGR of 12.28% during the period 2016-2020. ... analysis with inputs from industry experts. The report covers the market ... also includes a discussion of the key vendors operating in this ...
(Date:6/22/2016)... June 22, 2016  The American College of Medical Genetics ... Executive Magazine as one of the fastest-growing trade shows ... at the Bellagio in Las Vegas . ... percentage of growth in each of the following categories: net ... and number of attendees. The 2015 ACMG Annual Meeting was ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
Breaking Biology News(10 mins):